NEW YORK (GenomeWeb News) – Illumina said after the close of the market Thursday that it has completed its $450 million acquisition of Verinata Health.

The deal, which was inked in early January, provides Illumina with Verinata's Verifi non-invasive prenatal test for detecting trisomy 21, 18, and 13. The test analyzes cell-free fetal DNA using next-generation sequencing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.